Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SCP & CO Healthcare Acquisition CoSHACU · Entity 136098 | Director | August 17, 2021 | August 24, 2021 |
| Starling Oncology, Inc.TOI · Entity 5327 | Director | July 27, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SCP & CO Healthcare Acquisition Co
Report date August 17, 2021 · Filed August 24, 2021
This filing explicitly reported no securities owned.
Starling Oncology, Inc.
Report date July 27, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 205,716 |
Reported balance
After 2026-07-27 transaction · row 1
1 source rowRow 1 · 2026-07-27 · Grant · Acquired 33,133 · Balance 205,716 F1: Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AdaptHealth Corp.
Report date November 08, 2019 · Filed November 14, 2019
Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2019-11-08 transaction · row 1
1 source rowRow 1 · 2019-11-08 · Other · Disposed 6,087 · Balance 20,000 F1: Securities transferred by the reporting person to certain equityholders and employees of AdaptHealth Holdings LLC in connection with the closing of the business combination transaction between the issuer and AdaptHealth Holdings LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities transferred by the reporting person to certain equityholders and employees of AdaptHealth Holdings LLC in connection with the closing of the business combination transaction between the issuer and AdaptHealth Holdings LLC.
Oak Street Health, Inc.
Report date May 02, 2023 · Filed May 02, 2023
Section 16 reporting ended · disclosed 2023-05-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-05-02 transaction · row 1
1 source rowRow 1 · 2023-05-02 · Disposition to issuer · Disposed 215,224 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of February 7, 2023 (the "Merger Agreement"), by and among the Issuer, CVS Pharmacy, Inc. ("Parent"), Halo Merger Sub Corp. ("Merger Sub") and, for the limited purposes set forth therein, CVS Health Corporation, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $39.00 per share in cash, without interest and subject to applicable tax withholdings (the "Per Share Price"). F2: (Continued from Footnote 1) The shares of the Issuer's common stock reported as disposed by the Reporting Person include vested restricted stock units ("RSUs") of the Issuer which, pursuant to the Merger Agreement, were, at the Effective Time, automatically canceled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the product of the Per Share Price multiplied by the number of shares of the Issuer's common stock subject to such RSUs as of immediately prior to the Effective Time. F3: Includes 219 shares of the Issuer's common stock which, following the transaction reported on the Reporting Person's Form 4 filed on November 8, 2021, were inadvertently omitted from the total shares of the Issuer's common stock reported as beneficially owned by the Reporting Person on subsequent Form 4s filed by the Reporting Person due to administrative error. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.00 · Expires 2030-08-05 | Direct | 0 |
Reported balance
After 2023-05-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-02 · Disposition to issuer · Disposed 3,501 · Balance 0 F4: Pursuant to the Merger Agreement, this option was automatically canceled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the number of shares of the Issuer's common stock subject to such option as of immediately prior to the Effective Time multiplied by the excess of the Per Share Price over the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated as of February 7, 2023 (the "Merger Agreement"), by and among the Issuer, CVS Pharmacy, Inc. ("Parent"), Halo Merger Sub Corp. ("Merger Sub") and, for the limited purposes set forth therein, CVS Health Corporation, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $39.00 per share in cash, without interest and subject to applicable tax withholdings (the "Per Share Price").
F2: (Continued from Footnote 1) The shares of the Issuer's common stock reported as disposed by the Reporting Person include vested restricted stock units ("RSUs") of the Issuer which, pursuant to the Merger Agreement, were, at the Effective Time, automatically canceled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the product of the Per Share Price multiplied by the number of shares of the Issuer's common stock subject to such RSUs as of immediately prior to the Effective Time.
F3: Includes 219 shares of the Issuer's common stock which, following the transaction reported on the Reporting Person's Form 4 filed on November 8, 2021, were inadvertently omitted from the total shares of the Issuer's common stock reported as beneficially owned by the Reporting Person on subsequent Form 4s filed by the Reporting Person due to administrative error.
F4: Pursuant to the Merger Agreement, this option was automatically canceled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the number of shares of the Issuer's common stock subject to such option as of immediately prior to the Effective Time multiplied by the excess of the Per Share Price over the exercise price per share of such option.
UNIVERSAL AMERICAN CORP.
Report date April 28, 2017 · Filed May 02, 2017
Section 16 reporting ended · disclosed 2017-05-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 1
1 source rowRow 1 · 2017-04-28 · Disposition to issuer · Disposed 10,430 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of November 17, 2016 (the "Merger Agreement"), by and among Universal American Corp. (the "Company"), WellCare Health Plans, Inc. and Wind Merger Sub, Inc., at the Effective Time (as defined in the Merger Agreement), each of these shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the per share merger consideration of $10.00. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated as of November 17, 2016 (the "Merger Agreement"), by and among Universal American Corp. (the "Company"), WellCare Health Plans, Inc. and Wind Merger Sub, Inc., at the Effective Time (as defined in the Merger Agreement), each of these shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the per share merger consideration of $10.00.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2026 Filed Jul 29, 2026 22:56 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 33,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-26-000993 · ownership.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,716 F1 · kind: Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. Read SEC document |
| April 16, 2026 Filed Apr 16, 2026 23:27 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon Stock | 38,433 | $3.50 | $134,534.72 |
DisclosureSEC source: 0001079973-26-000499 · ownership.xml · nonDerivative · entry 2 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,583 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 16, 2025. F3 · price: Price of $3.5005 was the volume weighted average selling price of all sales by the reporting person on April 16, 2026 within a one-dollar range. Actual prices ranged from $3.5000 to $3.5050. The reporting person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 23:27 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon Stock | 57,286 | $3.50 | $200,598.39 |
DisclosureSEC source: 0001079973-26-000499 · ownership.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,016 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 16, 2025. F2 · price: Price of $3.5017 was the volume weighted average selling price of all sales by the reporting person on April 14, 2026 within a one-dollar range. Actual prices ranged from $3.5000 to $3.5300. The reporting person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:25 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 40,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001553350-25-000147 · ownership.xml · nonDerivative · entry 2 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,302 F2 · shares: Represents restricted stock units that were fully vested upon grant. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:25 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 50,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001553350-25-000147 · ownership.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,179 F1 · shares: Represents restricted stock units that vest in full on Issuer's 2026 annual stockholder meeting date, subject to continued service with the Issuer through such vesting date. Read SEC document |
| November 22, 2024 Filed Nov 25, 2024 21:23 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 56,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001799191-24-000053 · wk-form4_1732569806.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,253 F1 · shares: Represents restricted stock units that vest in full on TOI, Inc.'s 2025 annual shareholder meeting date, subject to continued service with the Company through such vesting date. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 22:27 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 53,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-042824 · wk-form4_1703802464.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,253 F1 · price: Represents restricted stock units that vest in full on TOI, Inc. 2024 annual shareholder meeting date, subject to continued service with the Company through such vesting date. Read SEC document |
| May 02, 2023 Filed May 2, 2023 19:56 UTC | Oak Street Health, Inc. OSH · Entity 113906 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 3,501 | $18.00 Strike: $21.00 | $63,018.00 |
DisclosureSEC source: 0000899243-23-012031 · doc4.xml · derivative · entry 2 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock, $0.001 par value · 3,501 shares Expires 2030-08-05 F4 · derivative.exercise_date: Pursuant to the Merger Agreement, this option was automatically canceled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the number of shares of the Issuer's common stock subject to such option as of immediately prior to the Effective Time multiplied by the excess of the Per Share Price over the exercise price per share of such option. Read SEC document |
| May 02, 2023 Filed May 2, 2023 19:56 UTC | Oak Street Health, Inc. OSH · Entity 113906 | Disposition to issuerCommon stock, $0.001 par value | 215,224 | $39.00 | $8,393,736.00 |
DisclosureSEC source: 0000899243-23-012031 · doc4.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to that certain Agreement and Plan of Merger, dated as of February 7, 2023 (the "Merger Agreement"), by and among the Issuer, CVS Pharmacy, Inc. ("Parent"), Halo Merger Sub Corp. ("Merger Sub") and, for the limited purposes set forth therein, CVS Health Corporation, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $39.00 per share in cash, without interest and subject to applicable tax withholdings (the "Per Share Price"). F2 · kind: (Continued from Footnote 1) The shares of the Issuer's common stock reported as disposed by the Reporting Person include vested restricted stock units ("RSUs") of the Issuer which, pursuant to the Merger Agreement, were, at the Effective Time, automatically canceled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the product of the Per Share Price multiplied by the number of shares of the Issuer's common stock subject to such RSUs as of immediately prior to the Effective Time. F3 · shares: Includes 219 shares of the Issuer's common stock which, following the transaction reported on the Reporting Person's Form 4 filed on November 8, 2021, were inadvertently omitted from the total shares of the Issuer's common stock reported as beneficially owned by the Reporting Person on subsequent Form 4s filed by the Reporting Person due to administrative error. Read SEC document |
| April 23, 2023 Filed Apr 25, 2023 17:49 UTC | Oak Street Health, Inc. OSH · Entity 113906 | GrantCommon Stock, $0.001 par value | 5,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025598 · doc4.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,005 F1 · kind: Represents Restricted Stock Units (RSUs) issued to the Reporting Person under the Oak Street Health, Inc. Omnibus Incentive Plan. These RSUs will vest the day immediately prior to the date of the next annual meeting of the stockholders of the Company occurring after the date of grant so long as the Reporting Person continues to serve on the Board through such date. Read SEC document |
| March 17, 2023 Filed Mar 22, 2023 01:06 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 19,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-008838 · wf-form4_167944717325553.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,393 F1 · shares: Represents restricted stock units that vest in full on March 16, 2024, subject to continued service with the Company through such vesting date. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 22:32 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 22,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001799191-22-000034 · edgardoc.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,242 F1 · price: Represents restricted stock units that vest in full on May 17, 2023, subject to continued service with the Company through such vesting date. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 23:08 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon Stock | 15,994 | $2.13 | $34,083.21 |
DisclosureSEC source: 0001799191-22-000006 · edgardoc.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,534 F1 · kind: The sale was pursuant to Mohit Kaushal's Rule 10b5-1 Trading Plan that was established on August 25, 2022. F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 14, 2022 within a one-dollar range. Actual prices ranged from $2.08 to $2.18. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 00:32 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 4,798 | $4.96 | $23,798.08 |
DisclosureSEC source: 0001628280-22-027011 · wf-form4_166674432949922.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,528 F1 · kind: The sale was made pursuant to Mohit Kaushal's Rule 10b5-1 Trading Plan that was established on August 25, 2022. F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on October 24, 2022 within a one-dollar range. Actual prices ranged from $4.62 to $5.18. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 18:57 UTC | Oak Street Health, Inc. OSH · Entity 113906 | GrantCommon Stock, $0.001 par value | 10,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026065 · doc4.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,865 Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:35 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 4,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-007097 · wf-form4_164807852431445.xml · nonDerivative · entry 2 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,326 Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:35 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 15,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-007097 · wf-form4_164807852431445.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,528 F1 · shares: Represents restricted stock units that vest in full on November 12, 2022, subject to continued service with the Company through such vesting date. F1 · price: Represents restricted stock units that vest in full on November 12, 2022, subject to continued service with the Company through such vesting date. Read SEC document |
| November 12, 2021 Filed Nov 17, 2021 02:54 UTC | Starling Oncology, Inc. TOI · Entity 5327 | ConversionClass B Common Stock · Derivative | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-140220 · tm2132979-14_4seq1.xml · derivative · entry 3 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as deifned below), and have no expiration date. F1 · price: The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as deifned below), and have no expiration date. F1 · derivative.exercise_date: The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as deifned below), and have no expiration date. F1 · derivative.expiration_date: The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as deifned below), and have no expiration date. Read SEC document |
| November 12, 2021 Filed Nov 17, 2021 02:54 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Disposition to issuerCommon Stock | 4,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-140220 · tm2132979-14_4seq1.xml · nonDerivative · entry 2 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,534 F3 · price: On November 12, 2021, in connection with the Business Combination, Mr. Kaushal, forfeited 4,466 of his shares of the Issuer's common stock to the Issuer pursuant to the Stockholder Support Agreement, dated as of June 28, 2021, by and among, DFP and TOI and certain DFP directors and officers, including Mr. Kaushal. F2 · acquired: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger, dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination. In connection with the Business Combination, the Class A common stock was converted to Common Stock of the Issuer, pursuant to a reclassification exempt under Rule 16b-7. Read SEC document |
| November 12, 2021 Filed Nov 17, 2021 02:54 UTC | Starling Oncology, Inc. TOI · Entity 5327 | ConversionCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-140220 · tm2132979-14_4seq1.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as deifned below), and have no expiration date. F2 · price: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger, dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination. In connection with the Business Combination, the Class A common stock was converted to Common Stock of the Issuer, pursuant to a reclassification exempt under Rule 16b-7. F1 · acquired: The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as deifned below), and have no expiration date. F2 · acquired: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger, dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination. In connection with the Business Combination, the Class A common stock was converted to Common Stock of the Issuer, pursuant to a reclassification exempt under Rule 16b-7. Read SEC document |
| November 12, 2021 Filed Nov 19, 2021 01:24 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionClass B Common Stock · Derivative | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-141458 · tm2133425-2_4aseq1.xml · derivative · entry 2 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as defined below), and have no expiration date. F1 · price: The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as defined below), and have no expiration date. F1 · derivative.exercise_date: The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as defined below), and have no expiration date. F1 · derivative.expiration_date: The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as defined below), and have no expiration date. Read SEC document |
| November 12, 2021 Filed Nov 19, 2021 01:24 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-141458 · tm2133425-2_4aseq1.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as defined below), and have no expiration date. F2 · price: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger, dated as June 28, 2021, by and among DFP Healthcare Acquisitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surviving corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination. In connection with the Business Combination, the Class A common stock was converted to Common Stock of the Issuer, pursuant to a reclassification exempt under Rule 16b-7. F1 · acquired: The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as defined below), and have no expiration date. F2 · acquired: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger, dated as June 28, 2021, by and among DFP Healthcare Acquisitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surviving corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination. In connection with the Business Combination, the Class A common stock was converted to Common Stock of the Issuer, pursuant to a reclassification exempt under Rule 16b-7. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 17:10 UTC | Oak Street Health, Inc. OSH · Entity 113906 | GrantCommon Stock, $0.001 par value | 4,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-063411 · doc4.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,492 F1 · kind: Represents Restricted Stock Units (RSUs) issued to the Reporting Person under the Oak Street Health, Inc. Omnibus Incentive Plan. These RSUs will vest the day immediately prior to the date of the next annual meeting of the stockholders of the Company occurring after the date of grant so long as the Reporting Person continues to serve on the Board through such date. Read SEC document |
| December 04, 2020 Filed Dec 16, 2020 16:39 UTC | Oak Street Health, Inc. OSH · Entity 113906 | Exercise / conversionEmployee Stock Option (right to Buy) · Derivative | 219 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-20-063812 · doc4.xml · derivative · entry 2 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 219 shares Expires 2030-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: No shares of the Issuer's common stock have been sold by the Reporting Person. These shares are subject to a Lock-Up Agreement for a period of 180 days following the date of the final prospectus relating to the initial public offering of the Issuer's common stock. Read SEC document |
| December 04, 2020 Filed Dec 16, 2020 16:39 UTC | Oak Street Health, Inc. OSH · Entity 113906 | Exercise / conversionCommon stock, $0.001 par value | 219 | $21.00 | $4,599.00 |
DisclosureSEC source: 0001209191-20-063812 · doc4.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: No shares of the Issuer's common stock have been sold by the Reporting Person. These shares are subject to a Lock-Up Agreement for a period of 180 days following the date of the final prospectus relating to the initial public offering of the Issuer's common stock. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 08:46 UTC | Oak Street Health, Inc. OSH · Entity 113906 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 219 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052175 · doc4.xml · derivative · entry 3 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219 Underlying: Common Stock, par value $0.001 · 219 shares Expires 2030-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: No shares of the Issuer's common stock have been sold by the Reporting Person. These shares are subject to a Lock-Up Agreement for a period of 180 days following the date of the final prospectus relating to the initial public offering of the Issuer's common stock. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 08:46 UTC | Oak Street Health, Inc. OSH · Entity 113906 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,612 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052175 · doc4.xml · derivative · entry 2 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 2,612 shares Expires 2030-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: No shares of the Issuer's common stock have been sold by the Reporting Person. These shares are subject to a Lock-Up Agreement for a period of 180 days following the date of the final prospectus relating to the initial public offering of the Issuer's common stock. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 08:46 UTC | Oak Street Health, Inc. OSH · Entity 113906 | Exercise / conversionCommon Stock, $0.001 par value | 2,831 | $21.00 | $59,451.00 |
DisclosureSEC source: 0001209191-20-052175 · doc4.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: No shares of the Issuer's common stock have been sold by the Reporting Person. These shares are subject to a Lock-Up Agreement for a period of 180 days following the date of the final prospectus relating to the initial public offering of the Issuer's common stock. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 21:12 UTC | Oak Street Health, Inc. ?OSH? · Entity 113906 | GrantCommon stock, $0.001 par value | 9,524 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022210 · doc4.xml · nonDerivative · entry 2 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,214 Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 21:12 UTC | Oak Street Health, Inc. ?OSH? · Entity 113906 | OtherCommon stock, $0.001 par value | 182,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022210 · doc4.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,690 F1 · kind: These shares of common stock of Oak Street Health, Inc. (the "Issuer") were issued in connection with the closing of the Issuer's initial public offering on August 10, 2020 (the "Closing Date") in exchange for incentive units pursuant to the transactions contemplated by the Master Structuring Agreement dated August 10, 2020, by and among the Issuer, OSH Merger Sub 1, LLC, Quantum Strategic Partners Ltd., General Atlantic OSH Interholdco L.P., OSH Management Holdings, LLC ("Management Holdings"), Oak Street Health, LLC and Geoffrey Price dated August 10, 2020 (the "Organizational Transactions"). F2 · kind: Represents shares of the Issuer's common stock, par value $0.001 (the "Shares") issued in exchange for vested and unvested incentive units in of Management Holdings in connection with the Organizational Transactions. The issuance of these securities was approved by the Issuer's board of directors under Rule 16b-3. Shares issued in exchange for the unvested incentive units were issued under the Oak Street Health Omnibus Incentive Plan (the "Plan"). Read SEC document |
| August 05, 2020 Filed Aug 12, 2020 21:12 UTC | Oak Street Health, Inc. ?OSH? · Entity 113906 | GrantEmployee Stock Options (Right to Buy) · Derivative | 3,501 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022210 · doc4.xml · derivative · entry 5 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,501 Underlying: Common Stock, par value $0.001 · 3,501 shares Expires 2030-08-05 F5 · derivative.exercise_date: Represents options issued under the Plan in exchange for unvested performance-vesting incentive units in Management Holdings in connection with the Organizational Transactions. These options will cliff vest 100% on August 10, 2022. Read SEC document |
| August 05, 2020 Filed Aug 12, 2020 21:12 UTC | Oak Street Health, Inc. ?OSH? · Entity 113906 | GrantEmployee Stock Options (Right to Buy) · Derivative | 438 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022210 · doc4.xml · derivative · entry 4 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438 Underlying: Common Stock, par value $0.001 · 438 shares Expires 2030-08-05 F4 · derivative.exercise_date: Represents options issued under the Plan in exchange for unvested time-vesting incentive units in Management Holdings in connection with the Organizational Transactions. These options will vest in two equal quarterly installments beginning on August 22, 2020. Read SEC document |
| August 05, 2020 Filed Aug 12, 2020 21:12 UTC | Oak Street Health, Inc. ?OSH? · Entity 113906 | GrantEmployee Stock Options (Right to Buy) · Derivative | 2,612 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022210 · doc4.xml · derivative · entry 3 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,612 Underlying: Common Stock, par value $0.001 · 2,612 shares Expires 2030-08-05 F3 · derivative.exercise_date: Represents options issued under the Plan in exchange for vested incentive units in Management Holding in connection with the Organizational Transactions. These options are fully vested and exercisable. Read SEC document |
| November 08, 2019 Filed Nov 14, 2019 02:05 UTC | AdaptHealth Corp. AHCO · Entity 5183 | OtherClass A Common Stock | 6,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-063526 · a4.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: Securities transferred by the reporting person to certain equityholders and employees of AdaptHealth Holdings LLC in connection with the closing of the business combination transaction between the issuer and AdaptHealth Holdings LLC. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 21:04 UTC | AdaptHealth Corp. DFBH · Entity 5183 | OtherCommon Stock | 3,913 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-022207 · a4.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,087 F1 · kind: 3,913 shares were forfeited to the Issuer at no cost in connection with the expiration of the underwriters' over-allotment option, as described in the Issuer's registration statement on Form S-1, as amended (File No. 333-222376). F1 · price: 3,913 shares were forfeited to the Issuer at no cost in connection with the expiration of the underwriters' over-allotment option, as described in the Issuer's registration statement on Form S-1, as amended (File No. 333-222376). Read SEC document |
| April 28, 2017 Filed May 2, 2017 19:03 UTC | UNIVERSAL AMERICAN CORP. UAM · Entity 176574 | Disposition to issuerCommon Stock | 10,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-17-000939 · es1700591_4-kaushal.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated as of November 17, 2016 (the "Merger Agreement"), by and among Universal American Corp. (the "Company"), WellCare Health Plans, Inc. and Wind Merger Sub, Inc., at the Effective Time (as defined in the Merger Agreement), each of these shares of the Company's common stock was cancelled and converted into the right to receive an amount in cash equal to the per share merger consideration of $10.00. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 17:14 UTC | UNIVERSAL AMERICAN CORP. UAM · Entity 176574 | GrantCommon Stock | 10,430 | $9.98 | $104,091.40 |
DisclosureSEC source: 0001593968-16-001291 · primary_01.xml · nonDerivative · entry 1 Kaushal Mohit · CIK 0001683021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,430 F1 · shares: Represents grant of restricted stock which vests in four equal annual installments beginning December 7, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.